Vigil Neuroscience Issuance Of Capital Stock Over Time

VIGL Stock  USD 2.07  0.12  5.48%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vigil Neuroscience Performance and Vigil Neuroscience Correlation.
For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.
  
Issuance Of Capital Stock is expected to rise to -7,600 this year.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.07)
Return On Assets
(0.40)
Return On Equity
(0.70)
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Issuance Of Capital Stock Analysis

Compare Vigil Neuroscience and related stocks such as Molecular Partners, Pmv Pharmaceuticals, and Monte Rosa Therapeutics Issuance Of Capital Stock Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
MOLN392 K392 K392 K392 K392 K392 K392 K392 K392 KM113.6 M51.5 M0.00.00.0
PMVP0.00.00.00.00.00.00.00.00.061.9 M293 M(1.4 M)M35.1 M52.1 M
GLUE14.2 M14.2 M14.2 M14.2 M14.2 M14.2 M14.2 M14.2 M14.2 M14.2 M60.5 M380.8 M20.1 M0.00.0
TRDA0.00.00.00.00.00.00.00.00.00.049.8 M306.5 M190.7 M19.4 M18.4 M
THRD10.8 M10.8 M10.8 M10.8 M10.8 M10.8 M10.8 M10.8 M10.8 M10.8 M10.8 M135.7 M198.2 M0.00.0
CGEM10001000100010001000100010001000100084.2 M139.1 M267.3 M38.4 M44.1 M41.9 M
EWTX24.8 M24.8 M24.8 M24.8 M24.8 M24.8 M24.8 M24.8 M24.8 M24.8 M120.1 M186.1 M129.2 M(555 K)(527.2 K)
RLYB31.6 M31.6 M31.6 M31.6 M31.6 M31.6 M31.6 M31.6 M31.6 M31.6 M145.2 M86.2 M51.5 M0.00.0
PEPGMMMMMMMMMMM149 M114.3 M0.00.0
TYRA0.00.00.00.00.00.00.00.00.00.023.3 M310.8 M181.3 M208.5 M141.8 M
CMPX49.2 M49.2 M49.2 M49.2 M49.2 M49.2 M49.2 M49.2 M49.2 M60.5 M60.5 M128.3 M76.2 M3.1 MM
PRTC152 M152 M152 M152 M152 M152 M152 M152 M152 M50.3 MM12.9 M332 K1.2 M1.1 M
OPT8.8 M8.8 M8.8 M8.8 M8.8 M8.8 M8.8 M8.8 M8.8 M33.7 M105.5 M0.081.8 M158.8 M166.8 M
PHVS4.5 M4.5 M4.5 M4.5 M4.5 M4.5 M4.5 M4.5 M4.5 M22.5 M102.5 M156.8 M9.6 M64.2 M66 M

Vigil Neuroscience and related stocks such as Molecular Partners, Pmv Pharmaceuticals, and Monte Rosa Therapeutics Issuance Of Capital Stock description

My Equities

My Current Equities and Potential Positions

Vigil Neuroscience
VIGL
ClassificationPharmaceutical Products
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 2.07
When determining whether Vigil Neuroscience is a strong investment it is important to analyze Vigil Neuroscience's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vigil Neuroscience's future performance. For an informed investment choice regarding Vigil Stock, refer to the following important reports:
Check out Vigil Neuroscience Performance and Vigil Neuroscience Correlation.
For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Vigil Neuroscience technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Vigil Neuroscience technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Vigil Neuroscience trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...